TFF Pharmaceuticals announced that it has leased a new 3,500+ square foot R&D facility in Austin, Texas, USA, that will house additional lab space, as well as equipment for the production of preclinical supplies, significantly expanding the company's capabilities. TFF also said that it will continue its relationship with the University of Texas at Austin, where … [Read more...] about TFF Pharmaceuticals expands with new R&D facility
Products and Services
DFE launches Lactohale 400 anhydrous inhalation grade lactose
DFE Pharma has announced the launch of a new product in its range of Lactohale inhalation grade lactose products; Lactohale 400 milled anhydrous lactose is described as a grade for formulations "where a relatively good flow with some cohesiveness is required." According to the company, the median particle size of Lactohale 400 is 100μm, and DFE Pharma will work with … [Read more...] about DFE launches Lactohale 400 anhydrous inhalation grade lactose
H&T Presspart opens low-GWP MDI filling facility
Device maker H&T Presspart has announced the opening of a new laboratory scale facility at its Blackburn, UK Inhalation Product Technology Centre (IPTC) for filling metered dose inhalers with lower global warming potential (GWP) propellants, including both HFA 152a and HFO 1234ze. According to the company, which offers product development services and … [Read more...] about H&T Presspart opens low-GWP MDI filling facility
Helicon Health to distribute Adherium’s Hailie inhalor sensor in the UK
Adherium has announced that Helicon Health, a spin out from the UCL Centre for Health Informatics and Multi Professional Education, will market Adherium's Hailie inhaler sensors and monitoring service in the UK. According to the Helicon website, the company does three things: 1) "Deliver technological innovations that enable the virtual delivery of healthcare"; 2) … [Read more...] about Helicon Health to distribute Adherium’s Hailie inhalor sensor in the UK
CounterAct naloxone nasal spray cap gets Canadian patent
According to CounterAct, the Canadian Intellectual Property Office has issued a patent (3065307, "Prescription bottle cap capable of administering opioid overdose reversal agent") covering the company's naloxone nasal spray cap. CounterAct co-founder Todd Pizitz commented, "We are pleased to continue to add to our intellectual property protection with the addition of … [Read more...] about CounterAct naloxone nasal spray cap gets Canadian patent
Opiant invests €2 million for expanded production of Aptar nasal device for use with OPNT003
Opiant Pharmaceuticals announced that it has signed an agreement with Aptar Pharma for expanded production of Aptar’s Unidose device in order to support potential commercial demand for Opiant's OPNT003 intranasal nalmefene. The agreement includes €2 million from Opiant for installation of the necessary production equipment. Opiant recently initiated a rolling NDA … [Read more...] about Opiant invests €2 million for expanded production of Aptar nasal device for use with OPNT003
RxPack joins IPAC-RS as associate member
Device company RxPack has joined the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) as an associate member, the company said. RxPack is a joint venture between Lindal Group and Coster Group that was formed in 2021 to distribute metered dose inhaler and nasal spray devices as well as Coster's aerosol filling … [Read more...] about RxPack joins IPAC-RS as associate member
Gerresheimer to manufacture ICOone DPI for Phase 3 trials of ISR’s intranasal COVID-19 vaccine
Gerresheimer has announced that it will manufacture supplies of Iconovo's IcoOne dry powder inhaler for Phase 3 trials of ISR's intranasal COVID-19 vaccine and has started the design process for molding and manufacturing the device. In March 2021, Iconovo announced that it would develop an inhaled vaccine for ISR, and in July 2021, Icovono said that it was developing … [Read more...] about Gerresheimer to manufacture ICOone DPI for Phase 3 trials of ISR’s intranasal COVID-19 vaccine
Upperton Pharma Solutions announces plans to build new facility
CDMO Upperton Pharma Solutions, which recently launched a new nasal delivery development platform, has announced that it will invest £15 million in a new 50,000 sq ft facility in Nottingham, UK that will include new laboratory space and 10 times more GMP manufacturing space than the company has currently. The new facility will also have the ability to handle highly … [Read more...] about Upperton Pharma Solutions announces plans to build new facility
Lonza announces expansion of DPI testing capacity
CDMO Lonza has announced that it is adding dry powder inhaler testing capabilities at its facility in Tampa, FL, USA for increased DPI development capacity. Lonza, which established a Center of Excellence for DPI particle engineering and formulation in Bend, OR, USA in 2020, said that the new laboratories in the Florida location will include capabilities for handling … [Read more...] about Lonza announces expansion of DPI testing capacity